Related Experiment Videos

Gamma knife radiosurgery for prolactinomas

A M Landolt1, N Lomax

  • 1Gamma Knife Center, Klinik im Park, Zürich, Switzerland. 100023.1666@compuserve.com

Journal of Neurosurgery
|January 6, 2001
PubMed
Abstract

Insights

Gamma knife radiosurgery (GKS) shows promising results for prolactinoma remnants. Dopamine agonists may offer radioprotection, suggesting GKS discontinuation during drug therapy for better outcomes.

Area of Science:

  • Neurosurgery
  • Endocrinology
  • Radiation Oncology

Background:

  • Prolactinomas are pituitary tumors often treated with surgery and medication.
  • Tumor remnants after initial treatment pose a clinical challenge.
  • Dopamine agonists are standard medical therapy for prolactinomas.

Purpose of the Study:

  • To evaluate the efficacy of Gamma Knife radiosurgery (GKS) for prolactinoma remnants post-surgery.
  • To investigate the potential radioprotective effect of dopamine agonists in GKS treatment for prolactinomas.

Main Methods:

  • Retrospective analysis of 20 patients with prolactinoma remnants treated with GKS.
  • Assessment of prolactin (PRL) levels, need for medical treatment, and pregnancy outcomes.
  • Comparison of outcomes between patients treated with and without concurrent dopamine agonist therapy during GKS.

Main Results:

  • Successful treatment (normal PRL, drug discontinuation) in 5 patients.
  • Improvement (reduced medication or maintained PRL with reduced dose) in 11 patients.
  • Patients on dopamine agonists during GKS had significantly poorer outcomes compared to untreated patients.

Conclusions:

  • GKS demonstrates favorable results for prolactinoma remnants, potentially due to case selection.
  • Evidence suggests dopamine agonists may have a radioprotective effect, potentially hindering GKS efficacy.
  • Discontinuing dopamine agonist therapy before GKS may improve treatment outcomes.

Related Concept Videos